Jacqueline E. Shea - 26 Feb 2024 Form 4 Insider Report for INOVIO PHARMACEUTICALS, INC. (INO)

Role
Chief Executive Officer, Director
Signature
/s/ Jacqueline E. Shea
Issuer symbol
INO
Transactions as of
26 Feb 2024
Net transactions value
-$30,420
Form type
4
Filing time
28 Feb 2024, 17:09:13 UTC
Previous filing
17 May 2023
Next filing
13 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INO Common Stock Options Exercise +1,878 +11% 18,387 26 Feb 2024 Direct F1, F2
transaction INO Common Stock Tax liability $7,116 -872 -4.7% $8.16 17,515 26 Feb 2024 Direct F3
transaction INO Common Stock Options Exercise +5,853 +33% 23,368 26 Feb 2024 Direct F4
transaction INO Common Stock Tax liability $23,305 -2,856 -12% $8.16 20,512 26 Feb 2024 Direct F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INO Restricted Stock Unit Options Exercise $0 -1,878 -100% $0.000000* 0 26 Feb 2024 Common Stock 1,878 Direct F1, F2
transaction INO Restricted Stock Unit Options Exercise $0 -5,853 -50% $0.000000 5,852 26 Feb 2024 Common Stock 5,853 Direct F2, F4
transaction INO Common Stock Option Award $0 +69,733 $0.000000 69,733 28 Feb 2024 Common Stock 69,733 $8.46 Direct F6
transaction INO Restricted Stock Unit Award $0 +55,895 $0.000000 55,895 28 Feb 2024 Common Stock 55,895 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 5,635 restricted stock units was as follows: 1,879 shares vested on February 26, 2022; 1,878 shares vested on February 26, 2023; and 1,878 shares vested on February 26, 2024. Vested restricted stock units could be settled in shares of common stock, cash or a combination of both.
F2 Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024.
F3 The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein.
F4 Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 17,557 restricted stock units is as follows: 5,852 shares vested on February 26, 2023; 5,853 shares vested on February 26, 2024; and 5,852 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
F5 The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (4) herein.
F6 The vesting schedule for the 69,733 options is as follows: 17,434 shares vested on February 28, 2024; 17,433 shares will vest on February 28, 2025; 17,433 shares will vest on February 28, 2026; and 17,433 shares will vest on February 28, 2027.
F7 Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 55,895 restricted stock units is as follows: 18,632 shares will vest on February 26, 2025; 18,632 shares will vest on February 26, 2026; and 18,631 shares will vest on February 26, 2027. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.